CompletedPhase 1

Anti-Secretory Drug in Treatment of Acute Watery Diarrhea

Egypt50 participantsStarted 2018-06-01

Plain-language summary

In conclusion, racecadotril is an anti-secretory drug that exerts its antidiarrheal effect by inhibiting intestinal enkephalinase. It is effective in reducing the volume and frequency of stool output. racecadotril is well tolerated and safe by providing symptomatic relief and reducing the severity of diarrhea as an adjuvant therapy during the acute attack of gastroenteritis. It is recommended that the new generations of already discovered drugs for control of secretory diarrhea should be studied to discover the ones with fewer side effects to other systems in the body.

Who can participate

Age range6 Months – 5 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age group for six months - 5 years. * No or mild to moderate dehydration. * Alert patient (to tolerate oral intake since the drug is only available in oral form). Exclusion Criteria: * Patients with severe dehydration (inability to drink because of drowsiness). * Patients with any serious concomitant illness that needs antibiotic treatment. * If severe adverse events occur at any time. * Chronic diarrhea.

What they're measuring

Diarrheal episode

Timeframe: 1-3 months

Trial details

NCT IDNCT05216822

SponsorAssiut University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-07-31

View on ClinicalTrials.gov More Acute Watery Diarrhea trials